

May, 17<sup>th</sup>, 2021

In response to the reviewer's comments:

We understand the time and effort it takes to critically review a manuscript and appreciate your comments. Please see the response to the comments below:

Reviewer #1:

1. An abstract was added
2. We have added the pathological classification of lung NENs and commented that staging follows AJCC 8<sup>th</sup> edition.
3. We have made an addition to the manuscript to state that the studies listed (such as Wegner et al., Westin et al., Nussbaum et al., Anderson et al., Gosiain et al.) investigated the effectiveness of adjuvant therapy (consisting of radiation therapy or chemotherapy such as cisplatin and etoposide, carboplatin and etoposide, or temozolomide) in these low and intermediate grade bronchopulmonary tumors. These studies did not specifically list the type of therapy that the patients received, just chemotherapy or radiation therapy; thus, it is not possible to add what kind of therapy was used in each study.
4. Thank you.
5. We have included considerations for chemotherapy from NCCN and ESMO to table 1.
6. We have reviewed the manuscript and corrected misspellings and grammatical errors.
7. Thank you.

Science editor reviewer:

1. Self-citations. We have included 2 self-citations (references Singh S et al 2020 and Naraev BG et al 2019) out of the 55 references and fall within the guidelines of less than 10%.
2. The title is less than the 18-word maximum.
3. Author contributions were added.
4. PMID and DOI citation numbers were added to the reference list.